SG Americas Securities LLC Buys 19,084 Shares of Insmed Incorporated (NASDAQ:INSM)

SG Americas Securities LLC increased its stake in Insmed Incorporated (NASDAQ:INSM) by 770.4% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 21,561 shares of the biopharmaceutical company’s stock after acquiring an additional 19,084 shares during the period. SG Americas Securities LLC’s holdings in Insmed were worth $1,574,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of INSM. First Horizon Advisors Inc. lifted its position in Insmed by 83.4% in the second quarter. First Horizon Advisors Inc. now owns 631 shares of the biopharmaceutical company’s stock valued at $42,000 after purchasing an additional 287 shares during the last quarter. EntryPoint Capital LLC purchased a new position in shares of Insmed in the first quarter worth $33,000. Fidelis Capital Partners LLC bought a new stake in Insmed during the 1st quarter valued at $34,000. CWM LLC boosted its position in Insmed by 11.0% during the 2nd quarter. CWM LLC now owns 1,570 shares of the biopharmaceutical company’s stock valued at $105,000 after buying an additional 155 shares during the period. Finally, Nisa Investment Advisors LLC grew its holdings in Insmed by 8.2% in the 2nd quarter. Nisa Investment Advisors LLC now owns 1,778 shares of the biopharmaceutical company’s stock worth $119,000 after acquiring an additional 135 shares during the last quarter.

Insmed Stock Up 1.2 %

INSM stock opened at $71.37 on Wednesday. The company has a quick ratio of 2.53, a current ratio of 2.71 and a debt-to-equity ratio of 25.05. The business has a 50 day moving average of $73.91 and a 200 day moving average of $56.05. Insmed Incorporated has a twelve month low of $21.92 and a twelve month high of $80.53. The firm has a market cap of $10.61 billion, a PE ratio of -13.65 and a beta of 1.11.

Insmed (NASDAQ:INSM) last issued its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported ($1.94) earnings per share for the quarter, missing the consensus estimate of ($1.22) by ($0.72). The firm had revenue of $90.34 million during the quarter, compared to analysts’ expectations of $87.95 million. Insmed’s quarterly revenue was up 17.0% on a year-over-year basis. During the same period in the previous year, the firm earned ($1.78) EPS. On average, research analysts forecast that Insmed Incorporated will post -5.42 EPS for the current fiscal year.

Insider Activity

In related news, insider Orlov S. Nicole Schaeffer sold 37,575 shares of the business’s stock in a transaction that occurred on Tuesday, September 10th. The shares were sold at an average price of $71.50, for a total value of $2,686,612.50. Following the completion of the transaction, the insider now directly owns 100,100 shares in the company, valued at $7,157,150. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, insider Orlov S. Nicole Schaeffer sold 37,575 shares of the stock in a transaction on Tuesday, September 10th. The stock was sold at an average price of $71.50, for a total transaction of $2,686,612.50. Following the sale, the insider now directly owns 100,100 shares of the company’s stock, valued at $7,157,150. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Martina M.D. Flammer sold 13,436 shares of Insmed stock in a transaction dated Monday, September 16th. The stock was sold at an average price of $74.92, for a total value of $1,006,625.12. Following the completion of the sale, the insider now owns 106,134 shares of the company’s stock, valued at $7,951,559.28. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 78,882 shares of company stock worth $5,765,446 over the last 90 days. 4.60% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on INSM shares. Morgan Stanley increased their target price on shares of Insmed from $60.00 to $85.00 and gave the stock an “overweight” rating in a report on Friday, July 12th. JPMorgan Chase & Co. lifted their price objective on Insmed from $72.00 to $74.00 and gave the stock an “overweight” rating in a research report on Thursday, October 3rd. Truist Financial decreased their target price on Insmed from $88.00 to $85.00 and set a “buy” rating for the company in a report on Monday, August 12th. Stifel Nicolaus lifted their price target on shares of Insmed from $74.00 to $88.00 and gave the company a “buy” rating in a report on Friday, August 9th. Finally, TD Cowen upped their price objective on shares of Insmed from $75.00 to $98.00 and gave the stock a “buy” rating in a report on Friday, August 9th. One equities research analyst has rated the stock with a sell rating and sixteen have given a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $81.53.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.